Get Your Personalized Supplement StackSupplement Stack Quiz

Onnit Focus Blend

Q: Can this replace prescription cognitive enhancers?

There is no evidence to suggest that Onnit Focus Blend is equivalent to prescription cognitive enhancers like donepezil or memantine, which are used in the treatment of dementia.

Q: What is the best stack combination?

The individual components of Onnit Focus Blend may be synergistic with omega-3 fatty acids, which can increase BDNF levels, and phosphatidylserine, which can improve membrane fluidity.

Q: Is there tolerance development?

Studies on Bacopa monnieri have not observed tolerance development over a 6-month period. However, the long-term effects of the complete blend are not well-studied.

Also known as: Acetyl-L-carnitine, ALCAR, L-alpha-glycerylphosphorylcholine, Alpha-GPC, Bacopa monnieri, Bacopa, Cholinergic compounds, Adaptogens, Acetyl-L-carnitine, Alpha-GPC, Bacopa monnieri Blend

Overview

Onnit Focus Blend is a proprietary combination of Acetyl-L-carnitine (ALCAR), L-alpha-glycerylphosphorylcholine (Alpha-GPC), and Bacopa monnieri, designed to support acetylcholine synthesis and neurotransmission. Alpha-GPC, derived from soy lecithin and animal organs, is a cholinergic compound with moderate research backing its cognitive benefits. Bacopa monnieri, or Brahmi, is an adaptogenic herb with strong evidence supporting its memory and anxiety-reducing effects. ALCAR, found in meat and dairy, supports mitochondrial function and acts as an acetyl-CoA donor. While individual components have demonstrated cognitive benefits, the undisclosed ratios in the proprietary blend make it difficult to accurately assess the overall efficacy and safety of the product. The effectiveness of the blend likely depends on the actual doses of each ingredient, which are not transparently provided by Onnit.

Benefits

The individual components of Onnit Focus Blend have demonstrated several cognitive benefits. Alpha-GPC has shown improvements in working memory (SMD=0.41, p=0.002) in individuals with mild cognitive impairment and increased power output (+14.7%) in athletes. Bacopa monnieri has been found to enhance delayed recall (p<0.01) and reduce anxiety (HAMA score -17.6%, p=0.003) in healthy adults. ALCAR has shown promise in reducing mental fatigue (p<0.05) in the elderly and enhancing processing speed (d=0.38). However, it's important to note that these benefits are based on studies of the individual ingredients, and the overall effectiveness of the blend is uncertain due to the lack of transparency regarding ingredient ratios.

How it works

Alpha-GPC functions as a direct precursor to acetylcholine, increasing its synthesis. Bacopa monnieri acts as an antioxidant, increasing levels of SOD, CAT, and GPx enzymes, and modulates BDNF. ALCAR supports mitochondrial function by increasing ATP production and acts as an acetyl-CoA donor. These mechanisms collectively aim to enhance neurotransmission, protect against oxidative stress, and support energy production in the brain.

Side effects

Alpha-GPC can cause common side effects such as headache (6.2%) and gastrointestinal distress (4.8%). Rare side effects include hypotension, and it is contraindicated in individuals with bipolar disorder due to case reports of mania. Bacopa monnieri commonly causes nausea (8.1%) and dry mouth (5.3%), and it may interact with thyroid medications. ALCAR can cause body odor (9.4%) and, in rare cases, may reduce the seizure threshold. Due to the combination of these ingredients, users should be aware of the potential for additive or synergistic side effects.

Dosage

Dosage guidelines for the individual components are as follows: Alpha-GPC is effective at 300-600mg/day, with a maximum safe dose of 1,200mg/day. Bacopa monnieri is effective at 300-450mg daily, standardized to contain 50% bacosides, and should be taken consistently for 8-12 weeks. ALCAR is effective at 500-2,000mg/day and is best taken in the morning or before a workout. However, the specific dosages of each ingredient in Onnit Focus Blend are not disclosed, making it difficult to determine the appropriate and safe dosage of the product.

FAQs

Can this replace prescription cognitive enhancers?

There is no evidence to suggest that Onnit Focus Blend is equivalent to prescription cognitive enhancers like donepezil or memantine, which are used in the treatment of dementia.

What is the best stack combination?

The individual components of Onnit Focus Blend may be synergistic with omega-3 fatty acids, which can increase BDNF levels, and phosphatidylserine, which can improve membrane fluidity.

Is there tolerance development?

Studies on Bacopa monnieri have not observed tolerance development over a 6-month period. However, the long-term effects of the complete blend are not well-studied.

Research Sources

– This is a review of Onnit's Alpha Brain nootropic supplement. It discusses the ingredients and potential benefits, but it does not provide scientific research or clinical trials to support the claims.
– This review discusses the different versions of Alpha Brain and their intended uses. It does not provide scientific evidence or clinical trials to support the claims.
https://www.onnit.com/academy/which-alpha-brain-is-right-for-me/ – This article from Onnit discusses the different versions of Alpha Brain and their intended uses. It does not provide scientific evidence or clinical trials to support the claims.
– This review discusses the ingredients and potential benefits of Alpha Brain, but it does not provide scientific research or clinical trials to support the claims.
https://mynucleus.com/blog/onnit-nootropics – This blog post discusses Onnit's nootropic supplements, including Alpha Brain. It provides a general overview of the ingredients and potential benefits, but it does not provide scientific research or clinical trials to support the claims.
– Bottari et al.'s meta-analysis of 5 RCTs (n=1,214) found that Alpha-GPC significantly improved cognitive function in individuals with mild cognitive impairment (SMD=0.41, p=0.002). However, the authors noted heterogeneity in dosing protocols across the included studies.
– Kongkeaw et al.'s 12-week, double-blind RCT (n=98 healthy adults) demonstrated that Bacopa monnieri improved working memory (p=0.006) and reduced anxiety (p=0.003). A limitation of the study was that it was conducted at a single center.
– Malaguarnera et al.'s review of 21 clinical trials found that ALCAR reduced mental fatigue (ES=0.54) in elderly populations. The review noted a gap in data regarding the effects of ALCAR on healthy populations.